Fadogia Agrestis: Scientific Analysis
Proposed mechanisms of LH stimulation and testicular steroidogenesis, limited human data, animal toxicity findings, and an honest look at evidence gaps for a compound that has outpaced its research base.
Speculative Compound With Limited Human Evidence
Fadogia Agrestis is a Nigerian shrub extract proposed to raise luteinizing hormone (LH) and trigger testicular testosterone production. Animal studies show dose-dependent testosterone rises in rats. But zero human randomized controlled trials have been published. The same animal studies that show testosterone increases also report testicular tissue damage at higher doses.
This compound has been popularized far beyond what its evidence base supports. The mechanism is plausible but unconfirmed in humans. The safety profile is uncharacterized in humans. If you choose to use it, you are accepting more uncertainty than with most compounds we analyze. This article reflects that reality.
What Is Fadogia? Classification and Botanical Identity
Botanical Classification
Fadogia Agrestis is a shrub native to Nigeria and West Africa, part of the family Rubiaceae (the same family as coffee). It typically grows 1-2 meters tall in savanna and grassland regions. The plant has been used in traditional Nigerian medicine as an aphrodisiac and fever remedy, though formal ethnobotanical documentation is limited.
Active Constituents
The proposed bioactive compounds include alkaloids, saponins, anthraquinones, and flavonoids pulled mostly from the stem. The specific active molecules behind the proposed testosterone effects have not been isolated or individually characterized. That is a major limitation: unlike pharmaceutical compounds with defined molecular targets, Fadogia is a crude plant extract with several uncharacterized constituents. Which compound drives the proposed LH stimulation — if the effect is real in humans — is unknown.
Popularization
Fadogia Agrestis was a relatively obscure compound until a prominent neuroscience communicator's podcast brought it into mainstream awareness starting in 2021. The pairing of Fadogia with Tongkat Ali (Eurycoma longifolia) for natural testosterone optimization was pushed heavily, driving huge commercial demand despite the compound having zero human clinical trials. The gap between market adoption and scientific evidence for Fadogia is among the largest seen in compound analysis.
Evidence Reality Check: Fadogia Agrestis has been studied in about 12 published papers, almost all in rat models. There are zero published human randomized controlled trials. Zero human pharmacokinetic studies. Zero human dose-finding studies. Every claim about this compound's effects in humans is extrapolated from animal data or anecdotal reports.
Mechanism of Action — Proposed Pathway
The proposed mechanism of action for Fadogia Agrestis centers on stimulating the hypothalamic-pituitary-gonadal (HPG) axis to raise endogenous testosterone production. This mechanism comes entirely from animal studies and has not been confirmed in humans. The word "proposed" is used deliberately throughout this section.
Proposed LH Stimulation
The main proposed mechanism is a rise in circulating luteinizing hormone (LH). In rat studies (Yakubu et al., 2005), aqueous extract of Fadogia Agrestis stem produced dose-dependent increases in serum LH levels. How Fadogia raises LH — whether through direct GnRH stimulation at the hypothalamus, direct pituitary gonadotroph activation, or some other pathway — has not been worked out. The specific molecular target is unknown.
Testicular Steroidogenesis Activation
Elevated LH binds to LH receptors on Leydig cells in the testes, which fires the cAMP-PKA signaling cascade. That raises StAR protein (steroidogenic acute regulatory protein), which moves cholesterol into mitochondria for conversion to pregnenolone — the rate-limiting step in testosterone biosynthesis. The downstream enzyme cascade (3-beta-HSD, CYP17A1, 17-beta-HSD) converts pregnenolone to testosterone. This part of the mechanism is standard endocrine physiology — the question is whether Fadogia reliably triggers the upstream LH rise in humans.
Possible Direct Leydig Cell Activation
Some researchers have speculated that Fadogia saponins may also act directly on Leydig cells, bypassing the hypothalamic-pituitary signal entirely. That hypothesis is based on the observation that testosterone rises in animal studies looked disproportionate to the LH rise. But this mechanism has not been confirmed experimentally. It is speculative.
Downstream Testosterone Effects
If the upstream mechanism works as proposed, the downstream effects would follow standard testosterone physiology: more protein synthesis, better nitrogen retention, better libido, better mood and motivation, and possible body composition improvements. These are not unique to Fadogia — they are the expected consequences of any intervention that meaningfully raises endogenous testosterone.
The mechanism is biologically plausible. But plausible is not the same as proven. Every step in this proposed pathway has only been shown in animal models. The leap from rat endocrinology to human supplementation has not been validated by controlled human trials.
graph TD FA["Fadogia Agrestis
Stem Extract"] -->|"proposed"| HYPO["Hypothalamus
GnRH Release?"] FA -.->|"speculative"| LEYDIG2["Direct Leydig
Cell Activation?"] HYPO -->|"proposed"| PIT["Anterior Pituitary
LH Secretion"] PIT -->|"established physiology"| LEYDIG["Leydig Cells
LH Receptor Activation"] LEYDIG --> STAR["StAR Protein
Cholesterol Transport"] LEYDIG2 -.-> STAR STAR --> T["Testosterone
Production"] T --> E1["Protein Synthesis"] T --> E2["Libido / Mood"] T --> E3["Body Composition"] style FA fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a style T fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a style HYPO fill:#f4f4f5,stroke:#8a7d68,stroke-width:2px,color:#0a0a0a style PIT fill:#f4f4f5,stroke:#8a7d68,stroke-width:2px,color:#0a0a0a style LEYDIG fill:#f4f4f5,stroke:#8a7d68,stroke-width:2px,color:#0a0a0a style LEYDIG2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#8a7d68 style STAR fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style E1 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style E2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style E3 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
Clinical Research — What Exists and What Does Not
Study Landscape
The Fadogia Agrestis evidence base is small. About 12 published studies exist, almost all from Nigerian university laboratories using rat models. There are no human RCTs, no meta-analyses, no systematic reviews, and no human pharmacokinetic data. This section reports what exists honestly and flags what is missing.
Animal Testosterone Studies (Primary Evidence)
Yakubu and colleagues (2005) gave aqueous extract of Fadogia Agrestis stem to male Wistar rats at 18, 50, and 100 mg/kg body weight for 28 days. Results showed dose-dependent increases in serum testosterone: the 100 mg/kg group showed testosterone levels about 2x higher than control animals. Serum LH levels also rose in a dose-dependent way. This is the foundational study for all testosterone-boosting claims.
A follow-up study by the same group confirmed the testosterone increase and also reported bigger testicular weight and seminal vesicle weight, which fits androgen-driven tissue growth.
Testicular Toxicity Findings (Critical Concern)
The same Yakubu research group also published toxicological assessments. At higher doses (especially 100 mg/kg in rats), histological examination revealed degenerative changes in seminiferous tubules, interstitial edema, and altered Leydig cell morphology. These findings suggest that the doses producing the strongest testosterone increase also produced testicular tissue damage in animals.
Yakubu and colleagues (2008) reported that at 100 mg/kg, Fadogia produced higher testicular cholesterol (which suggests impaired cholesterol-to-pregnenolone conversion at toxic doses), elevated serum alkaline phosphatase, and histopathological changes consistent with cellular toxicity. The lower dose (18 mg/kg) showed minimal toxicity but also produced smaller testosterone effects.
Absence of Human Data
There are zero published human RCTs for Fadogia Agrestis as of February 2026. No human studies have measured testosterone response, LH response, safety biomarkers, optimal dosing, or long-term effects. Every human dosing protocol in the supplement market is extrapolated from rat data using allometric scaling — a method that introduces a lot of uncertainty, especially for toxicity thresholds.
| Evidence Category | Status | Confidence |
|---|---|---|
| Animal testosterone increase | Demonstrated in multiple rat studies | Moderate (animal only) |
| Animal LH increase | Demonstrated dose-dependently | Moderate (animal only) |
| Human testosterone increase | No published data | Unknown |
| Human safety profile | No published data | Unknown |
| Animal testicular toxicity | Confirmed at higher doses | Moderate-High |
| Long-term safety (any species) | No published data beyond 28 days | Unknown |
| Active compound identification | Not completed | Low |
graph TD ROOT["Evidence Quality
Comparison"] ROOT --> FA["Fadogia Agrestis"] ROOT --> TA["Tongkat Ali"] ROOT --> COQ["CoQ10
Reference Standard"] FA --> FA1["Human RCTs: 0"] FA --> FA2["Animal Studies: ~12"] FA --> FA3["Safety Data: Animal only"] FA --> FA4["Active Compound: Unidentified"] TA --> TA1["Human RCTs: 8+"] TA --> TA2["Animal Studies: 30+"] TA --> TA3["Safety Data: Human confirmed"] TA --> TA4["Active Compound: Eurycomanone"] COQ --> COQ1["Human RCTs: 500+"] COQ --> COQ2["Meta-analyses: Multiple"] COQ --> COQ3["Safety Data: Extensive"] COQ --> COQ4["Active Compound: Defined"] style ROOT fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a style FA fill:#f4f4f5,stroke:#2a2236,stroke-width:2px,color:#0a0a0a style TA fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a style COQ fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a style FA1 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#8a7d68 style FA2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style FA3 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#8a7d68 style FA4 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#8a7d68 style TA1 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style TA2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style TA3 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style TA4 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style COQ1 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style COQ2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style COQ3 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style COQ4 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
Evidence Gap Summary: The core problem with Fadogia Agrestis is not that the animal data is negative — it is that animal data is all that exists. Rat testosterone metabolism is different from human testosterone metabolism in meaningful ways. Compounds that raise testosterone in rats do not always do so in humans. And compounds that are safe at certain doses in rats may have different toxicity thresholds in humans. Without human data, we are running on inference.
Common Questions — Dosing, Cycling, and Stacking
These are the questions that drive most search traffic for this compound. Each answer is grounded in the evidence above — which means many answers include the phrase "we don't know."
Does Fadogia actually work?
In rats, it raises testosterone. In humans, we do not know. No controlled human trial has been published. Anecdotal reports from supplement users are mixed and cannot be separated from placebo effect, expectation bias, or the effects of other compounds taken alongside (most users take Fadogia stacked with Tongkat Ali).
How should I dose Fadogia?
The commonly cited dose is 400-600mg daily of stem extract, based on allometric scaling from the rat studies. This is not derived from human dose-finding research. Do not go over 600mg/day. Take in the morning. Cycle 8 weeks on, 4 weeks off minimum.
Should I stack it with Tongkat Ali?
This is the standard pairing. The rationale: Fadogia may raise LH (upstream signal) while Tongkat Ali may boost Leydig cell sensitivity to LH (downstream response). Tongkat Ali has a lot more human evidence and a better-characterized safety profile. If you are picking only one, pick Tongkat Ali. If stacking both, know that the synergy claim is theoretical.
Do I need to cycle Fadogia?
Yes. This is non-negotiable given the animal toxicity data. The clinically studied protocol is 8 weeks on, 4 weeks off. Some practitioners use shorter cycles. Without human chronic-use safety data, cycling is the only responsible approach.
Risk Profile Analysis — The Primary Concern
The risk profile of Fadogia Agrestis is fundamentally different from well-studied compounds like CoQ10 or omega-3s. The main concern is not a specific documented adverse effect in humans — it is the absence of human safety data entirely. You cannot call a compound safe when it has never been studied for safety in the target species.
Testicular Histological Changes (Animal Data)
Risk: Moderate-High Concern (Animal Data)
Rat studies at 100 mg/kg showed seminiferous tubule degeneration, interstitial edema, and Leydig cell morphological changes. At the lower 18 mg/kg dose, these effects were minimal. The human-equivalent dose extrapolation is imprecise, but any testicular toxicity in animal studies warrants serious caution — especially for a compound targeting the reproductive system.
No Human Safety Data
Risk: High Uncertainty
Zero human safety studies exist. No liver safety panels, no renal function monitoring, no endocrine panel tracking, no long-term follow-up in any human population. Every user is effectively an unmonitored test subject.
No Long-Term Studies
Risk: Completely Unknown
The longest animal study lasted 28 days. Many supplement users take Fadogia for months or years. The effects of chronic use on testicular tissue, liver function, kidney function, and cardiovascular health are entirely unknown in any species past one month.
Poor Quality Control Across Brands
Risk: Moderate-High
Fadogia Agrestis is sourced almost entirely from West Africa with limited supply chain transparency. The active constituents have not been standardized. Third-party testing is inconsistent across brands. Contamination with heavy metals, pesticides, or adulterants is a real concern. Most products cannot verify that they contain what the label claims.
Mandatory Cycling
Given the animal toxicity data, cycling is mandatory: 8 weeks on, 4 weeks off at minimum. This is not a conservative protocol — it is the floor. Some practitioners use 4 on / 2 off. Without human toxicity data to set safe chronic exposure limits, intermittent use is the only responsible protocol.
- Zero human safety trials — long-term safety completely unknown
- Testicular histological damage documented in animal studies at higher doses
- Active compounds not isolated — you are consuming a crude extract
- No standardization across products — dose consistency unreliable
- Premium pricing for a compound with minimal supporting evidence
- Must cycle 8 weeks on / 4 weeks off minimum — never use continuously
graph LR ROOT["Fadogia Agrestis
Risk Profile"] ROOT --> HIGH["HIGH CONCERN"] ROOT --> MOD["MODERATE CONCERN"] ROOT --> UNK["UNKNOWN"] HIGH --> H1["No human safety data"] HIGH --> H2["Testicular damage
in animal studies"] MOD --> M1["Poor quality control
across brands"] MOD --> M2["Crude extract with
unidentified actives"] MOD --> M3["Premium price for
limited evidence"] UNK --> U1["Long-term effects
in any species"] UNK --> U2["Hepatic safety"] UNK --> U3["Renal safety"] UNK --> U4["Cardiovascular effects"] style ROOT fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a style HIGH fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a style MOD fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a style UNK fill:#f4f4f5,stroke:#8a7d68,stroke-width:2px,color:#0a0a0a style H1 fill:#f4f4f5,stroke:#2a2236,stroke-width:2px,color:#0a0a0a style H2 fill:#f4f4f5,stroke:#2a2236,stroke-width:2px,color:#0a0a0a style M1 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style M2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style M3 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style U1 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#8a7d68 style U2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#8a7d68 style U3 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#8a7d68 style U4 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#8a7d68
Evidence Synthesis — An Honest Assessment
What the Evidence Supports
Fadogia Agrestis aqueous stem extract raises testosterone and LH in male Wistar rats in a dose-dependent way over 28 days. The proposed mechanism — LH stimulation driving testicular steroidogenesis — is biologically plausible and consistent with established HPG axis physiology. The compound has real pharmacological activity in animal models.
What the Evidence Does Not Support
The evidence does not support the claim that Fadogia Agrestis reliably raises testosterone in humans. It does not support the claim that it is safe for human use at any dose. It does not support long-term use. It does not support the synergy claims with Tongkat Ali. These are all extrapolations, and responsible analysis requires being honest about the difference between animal data and human evidence.
Comparison to Established Alternatives
Tongkat Ali (Eurycoma longifolia) has multiple human RCTs showing testosterone effects, cortisol reduction, and body composition improvements. Its active compound (eurycomanone) has been identified. Its safety profile has been established in human trials. If the goal is natural testosterone optimization with an evidence base, Tongkat Ali is the better choice by a wide margin. Fadogia is a speculative addition, not a foundation.
A compound that raises testosterone in rats and damages testicular tissue in the same studies should be approached with caution, not enthusiasm. The supplement industry has done the opposite with Fadogia. This analysis corrects that imbalance.
| Assessment Domain | Finding | Confidence |
|---|---|---|
| Mechanistic basis | Proposed LH stimulation; biologically plausible | Moderate — animal data only |
| Animal efficacy | Dose-dependent testosterone increase in rats | Moderate — limited study count |
| Human efficacy | No published data | Unknown |
| Animal safety | Testicular toxicity at higher doses | Moderate-High concern |
| Human safety | No published data | Unknown |
| Overall assessment | Conditional — proceed with caution if choosing to use | Low — insufficient human data |
For Physique Enhancement
The interest in Fadogia Agrestis among physique-focused people comes from its proposed ability to raise LH and, by extension, endogenous testosterone production. If the mechanism works in humans the way it does in rats, the downstream effects would include more protein synthesis, better nitrogen retention, and better body composition. These remain conditional claims.
Proposed LH-Testosterone Cascade
If Fadogia raises LH as animal data suggests, the expected physiological cascade is: higher LH binding to Leydig cell receptors, more StAR protein, more cholesterol-to-pregnenolone conversion, and ultimately higher free and total testosterone. For natural athletes, even modest testosterone increases within the physiological range can meaningfully affect recovery, training capacity, and lean mass retention during caloric deficits.
The Typical Stack: Fadogia + Tongkat Ali
The dominant protocol in the physique community pairs Fadogia with Tongkat Ali. The theoretical rationale: Fadogia raises the upstream LH signal while Tongkat Ali boosts downstream testicular sensitivity to that signal. That creates a proposed two-point amplification of the HPG axis. The stack is standard practice but the synergy has not been shown in any published study — human or animal.
For Cognitive Enhancement
Fadogia Agrestis has no direct cognitive mechanism. It does not cross the blood-brain barrier in any characterized way. It does not tune neurotransmitter systems. It does not affect mitochondrial function in neurons. It is not a nootropic.
Theoretical Cognitive Spillover
Any cognitive benefits from Fadogia would be entirely indirect, coming through testosterone optimization — if that effect happens in humans. Testosterone influences cognition through several documented pathways: better mood and motivation (androgen receptor activation in the limbic system), better spatial cognition (testosterone-dependent hippocampal function), less mental fatigue (correlation with free testosterone levels), and better drive and assertiveness (dopaminergic modulation by androgens).
Honest Assessment
If Fadogia meaningfully raises testosterone in a given person, they may notice subtle improvements in mood, motivation, and mental energy. These are not unique to Fadogia — they would happen with any intervention that raises testosterone. And the "if" in that sentence is doing a lot of work, given the absence of human efficacy data. This is a physique-first compound with theoretical cognitive spillover only. Do not take Fadogia for cognitive enhancement.
Better Options for Cognition: If cognitive optimization is your goal, compounds with direct, well-characterized neurological mechanisms and human clinical evidence are the right starting point — CoQ10 for mitochondrial support, omega-3 DHA for membrane structure, magnesium L-threonate for NMDA function, or established nootropics with published human data.
Conclusions and Conditional Protocols
Mechanism: Fadogia Agrestis is proposed to trigger LH release from the anterior pituitary, which drives testicular steroidogenesis and raises endogenous testosterone. A secondary hypothesis suggests direct Leydig cell activation. Both mechanisms come from animal studies only.
Evidence: Animal studies show dose-dependent testosterone rises in rats. The same studies show testicular tissue damage at higher doses. Zero human RCTs exist. Zero human safety studies exist. The active compounds have not been identified. The evidence base is among the weakest of any widely marketed supplement.
Conclusion: Fadogia Agrestis is a speculative supplement. If you choose to use it after reading this analysis, the protocol below reflects the most cautious approach supported by available data. This is not an endorsement — it is harm reduction for those who will use it regardless.
Product Evaluation
Product evaluations for Fadogia Agrestis are limited because quality options are limited. Most brands lack third-party verification, standardization, or supply chain transparency. Only one product has enough quality control to warrant consideration.
Frequently Asked Questions
Unknown with certainty. No human safety trials have been published. Animal studies show testicular tissue changes — including seminiferous tubule degeneration and Leydig cell damage — at higher doses (100 mg/kg in rats). At the lower doses used in human supplementation (400-600mg/day), these effects have not been tested in controlled human trials. The honest answer is that long-term safety in humans is uncharacterized. If you choose to use Fadogia, cycle 8 weeks on / 4 weeks off, do not go over 600mg/day, and monitor bloodwork.
In rat models, yes — dose-dependent rises have been shown across multiple studies. In humans, no published data exists. All human testosterone claims are extrapolated from animal data or based on anecdotal reports. The effect may translate to humans, but this has not been confirmed by any controlled trial.
This is the most common protocol, popularized by a prominent neuroscience communicator. The theoretical rationale: Fadogia triggers LH (upstream signal), Tongkat Ali boosts testicular sensitivity to LH (downstream response). Tongkat Ali has much stronger evidence than Fadogia, including multiple human RCTs. If picking only one, pick Tongkat Ali. If stacking both, know that the synergy has not been shown in any published study.
Yes — cycling is mandatory. Animal studies showing testicular toxicity at higher doses make continuous, long-term use a bad idea. The clinically studied protocol is 8 weeks on, 4 weeks off at minimum. Some practitioners use even shorter cycles. Without human chronic-use safety data, intermittent use with mandatory off-periods is the only responsible approach.
The commonly cited dose is 400-600mg daily of stem extract. That dose is extrapolated from animal studies and community use — no human dose-finding trial has been published. Do not go over 600mg/day. Higher doses in animal studies produced testicular toxicity. Take in the morning with food.
No. Tongkat Ali (Eurycoma longifolia) has a lot more human clinical evidence, including multiple randomized controlled trials showing effects on testosterone, cortisol, and body composition. Its active compound (eurycomanone) has been identified and characterized. Its safety profile has been established in human trials lasting up to 12 weeks. Fadogia has zero human RCTs and unidentified active compounds. If forced to pick one, Tongkat Ali is the evidence-based choice.
the V3 approach.
Every compound on this site is one piece. Protocols.is is the whole system — interaction checker, protocol explorer, biomarker tracker, weekly check-in, and pre-built protocols across every major goal. Evidence-cited. One place. One price.
Disclaimer
This article is for education and entertainment only. Nothing here is medical advice, diagnosis, or a prescription. Do not start, stop, or change any compound, supplement, or protocol without talking to a qualified physician. Many compounds covered on this site are unapproved research chemicals, prescription drugs, or substances that need direct medical supervision. Protocols.is does not diagnose, treat, or prescribe.